SCHEMBL3887465

SCHEMBL3887465

CCN1CCc2c([nH]c3ccc([N+](=O)[O-])cc23)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
GFER P55789 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
BAZ2B Q9UIF8 1/20 0.57
TRPV1 Q8NER1 4/20 0.51
GRIA1 P42261 1/20 0.50
GRIA2 P42262 1/20 0.50
GRIA3 P42263 1/20 0.50
GRIA4 P48058 1/20 0.50
LMNA P02545 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
HTT P42858 1/20 0.46
NCOA1 Q15788 1/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
FAAH O00519 1/20 0.46
ALDH1A1 P00352 1/20 0.45
HTR1A P08908 1/20 0.45
ACHE P22303 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3874478 0.91 MAPT (0.57) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL3874692 0.85 MAPT (0.56) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL3877880 0.84 MAPT (0.64) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL3877884 0.83 MAPT (0.62) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL5546886 0.81 MEN1 (0.51) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL3886166 0.79 BAZ2B (0.52) MEN1KMT2ABAZ2BHTR1AACHE
SCHEMBL21731608 0.79 MEN1 (0.55) MEN1KMT2ABAZ2BTRPV1HTR1A
SCHEMBL13328971 0.77 BAZ2B (0.71) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL31233605 0.75 MAPT (1.00) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL699222 0.75 MAPT (1.00) MAPTMEN1KMT2AGFERSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US disclosed
EP-1919475-B1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS ESTEVE LABOR DR (ES) 2009-03-11 EP disclosed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands HTR6, HTR5A, HTR1B MAPT 2845/4885MEN1 2781/4885KMT2A 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.